摘要 : Abstract The treatment of invasive aspergillosis caused by cryptic species remains a challenge due to the lack of randomised clinical trials and investigation of the efficacy and safety of different therapeutic strategies. We aime... 展开 Abstract The treatment of invasive aspergillosis caused by cryptic species remains a challenge due to the lack of randomised clinical trials and investigation of the efficacy and safety of different therapeutic strategies. We aimed to evaluate the in vitro activity of 23 conventional and new antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates by using the Clinical and Laboratory Standards Institute (CLSI) standard M38‐A3. The lowest geometric mean MIC values were found for luliconazole and lanoconazole (0.001?μg/ml), followed by anidulafungin (0.104?μg/ml), posaconazole (0.15?μg/ml), itraconazole (0.37?μg/ml), efinaconazole (0.5?μg/ml), voriconazole (0.51?μg/ml), tavaborole (0.72?μg/ml), and amphotericin B (0.79?μg/ml). In contrast, ketoconazole, terbinafine, econazole, tioconazole, ravuconazole, miconazole, nystatin, clotrimazole, griseofulvin, sertaconazole, natamycin, tolnaftate, and fluconazole had no or low activity. Further studies are required to determine how well this in vitro activity translates into in vivo efficacy. 收起